To read the full story, subscribe or sign in.

Complement-Blocking Strategy Against Bacterial Meningitis

Sep. 21, 2011

By Sharon Kingman

No Comments

BioWorld Asia

Today's news in brief

BioWorld

BioWorld briefs for Dec. 3, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 3, 2024.

Illustration of man holding magnifying glass to human body model showing muscle anatomy

In muscular dystrophies, gene therapies race the clock

BioWorld

Since the isolation of the gene that causes Duchenne muscular dystrophy (DMD), scientists have progressed in understanding the mechanisms that lead to muscular...

AI-generated illustration of heart and metabolic impact

Bridgebio, with FDA approval, faces Pfizer in ATTR

BioWorld

With the U.S. FDA approval of Attruby (acoramidis) for transthyretin amyloidosis with cardiomyopathy (ATTR-CM), Bridgebio Pharma Inc. is taking on an industry...

Radiopharma Telix acquires FAP-targeting agents for bladder cancer

BioWorld

Radiopharmaceutical company Telix Pharmaceuticals Ltd. has inked a deal worth up to AU$264 million (US$171 million) to license and develop next-generation...

Upgrade your daily dose of biopharma and medtech news

Complement-Blocking Strategy Against Bacterial Meningitis